Several other tyrosine kinase inhibitors (TKI) also induce CTL-driven anti-tumor immune responses, including sunitinib, a broad spectrum RTK inhibitor that targets VEGFR, PDGFRα, Ret, and Kit, which has been shown to reverse immune suppression by inhibiting STAT3 signaling in renal cell carcinoma [89]. Here, STAT3 is linked to neoplasm.